For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Halozyme, Inc.

USPTO Granted Patents = 76

CIPO Patents = 10

EPO Patents = 23

Trademarks = 7

Forward Citations = 1,473

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Gregory Ian Frost (38 out of 39 patents)

Louis Howard Bookbinder (30 out of 30 patents)

H Michael Shepard (28 out of 58 patents)

4. Ge Wei (23 out of 24 patents)

5. Anirban Kundu (23 out of 23 patents)

6. Robert James Connor (21 out of 22 patents)

7. Qiping Zhao (20 out of 20 patents)

8. Curtis B Thompson (8 out of 8 patents)

9. Kevin David Swanson (5 out of 23 patents)

10. Xiaoming Li (4 out of 18 patents)

11. Harold Michael Shepard (4 out of 4 patents)

12. Daniel Edward Vaughn (4 out of 4 patents)

13. Todd J Leadens, Ii (4 out of 4 patents)

14. Baylor Frantz (4 out of 4 patents)

15. Per Borgström (3 out of 9 patents)

Core Competencies:

Hyaluronidase Enzyme Formulations

PH20 Polypeptide Variants

Soluble Glycosaminoglycanases

Combination Therapy

Injection Device

Adenosine Deaminase-2

Therapeutic Proteins

Hyaluronan-Degrading Enzyme

Collagen-Mediated Diseases

Cellulite Treatment

Post-Prandial Glucose Control

76 patents: Sort by Forward Citations

1. D1107901 - Injection device (2025-12-30),

2. D1105416 - Injection device (2025-12-09),

3. D1092725 - Injection device (2025-09-09),

4. 12371685 - PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof (2025-07-29),

5. 12264345 - PH20 polypeptide variants, formulations and uses thereof (2025-04-01),

6. 12195773 - PH20 polypeptide variants, formulations and uses thereof (2025-01-14),

7. 12178860 - Hyaluronidase enzyme formulations for high volume administration (2024-12-31),

8. 12152262 - PH20 polypeptide variants, formulations and uses thereof (2024-11-26),

9. 12123035 - PH20 polypeptide variants, formulations and uses thereof (2024-10-22),

10. 12110520 - PH20 polypeptide variants, formulations and uses thereof (2024-10-08),

11. 12104185 - PH20 polypeptide variants, formulations and uses thereof (2024-10-01),

12. 12104184 - PH20 polypeptide variants, formulations and uses thereof (2024-10-01),

13. D1042806 - Injection device (2024-09-17),

14. 12091692 - PH20 polypeptide variants, formulations and uses thereof (2024-09-17),

15. 12077791 - PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof (2024-09-03),

Halozyme, Inc. is a biotechnology company that develops and commercializes novel oncology therapies. They create innovative drug delivery platforms to improve the effectiveness of various cancer treatments. With a focus on enzyme engineering and advanced tissue permeability technology, Halozyme aims to enhance the outcome of cancer therapies by enabling better drug delivery and targeting. Visit their website to learn more about their groundbreaking advancements in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

76 Patents

#79 in San Diego, CA

#1,111 in California

#4,652 in US

#9,510 in the World

San Diego, CA, United States of America

Halozyme, Inc.

Forward Citations = 1,473

46 inventors:

Gregory Ian Frost (38 out of 39 patents)

Louis Howard Bookbinder (30 out of 30 patents)

H Michael Shepard (28 out of 58 patents)

4. Ge Wei (23 out of 24 patents)

5. Anirban Kundu (23 out of 23 patents)

Please report any incorrect information to support@idiyas.com

Loading…